A Randomized, Multicenter, Single Blinded, ParallelStudy of the Safety of 100 mg and 200 mg OseltamivirAdministered Intravenously for the Treatment ofInfluenza in Patients Aged 13 Years
|Effective start/end date||12/28/09 → 12/31/12|
- HOFFMANN-LA ROCHE PHARMACEUTICALS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.